This study is for adults with a stubborn (refractory) or unexplained long-lasting cough. The study will test a medication called Taplucainium Inhalation Powder (NOC-110) to see how safe and effective it is. It's a double-blind study, meaning neither the doctors nor participants will know who gets the actual medicine or a placebo (a harmless pill that looks like the real thing). The study is 13 weeks long, and about 455 people will join. Participants must be over 18, with a cough lasting at least 12 months. They can't join if they have certain lung diseases, are pregnant, or have had certain infections recently.
- Participation lasts about 13 weeks, involving several visits.
- Participants will be screened for eligibility before joining.
- Potential risks include allergies or reactions to the medication.
How understandable was the trial content above?
Hard to understand
Easy to understand